KFAS
PRME icon

Keating Financial Advisory Services’s Prime Medicine PRME Stock Holding History

Keating Financial Advisory Services’s Portfolio PRME Stock Details PRME Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-59
Closed -$205 – 2688
2026
Q1 		$205 Buy
+59
New +$225 ﹤0.01% 2369

Other funds holding PRME

Alphabet Inc
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ARK Investment Management
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
Woodline Partners
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Keating Financial Advisory Services's PRME Position: Q2 2026 in Review

Keating Financial Advisory Services sold out of Prime Medicine (PRME) in Q2 2026, closing a stake of 59 shares — an estimated $205 sold.

Keating Financial Advisory Services first reported a position in PRME in Q1 2026 and held it in 1 quarter. The position peaked at $205 in Q1 2026. 187 funds tracked by Wall St. Rank hold PRME as of Q2 2026.

  • Keating Financial Advisory Services reported no remaining Prime Medicine position as of Q2 2026 after selling out during the quarter.
  • Keating Financial Advisory Services sold 59 Prime Medicine shares in Q2 2026, an estimated $205.
  • Keating Financial Advisory Services first reported a position in Prime Medicine in Q1 2026 and held it in 1 quarter.
  • Keating Financial Advisory Services's Prime Medicine position peaked at $205 in Q1 2026.
  • 187 funds tracked by Wall St. Rank held Prime Medicine as of Q2 2026.

Based on Keating Financial Advisory Services's 13F filing for Q2 2026, filed 11 Aug 2026.